Comparison of Disease Severity Classifications of Chronic Obstructive Pulmonary Disease: GOLD vs. STAR in Clinical Practice

被引:1
|
作者
Nishimura, Koichi [1 ,2 ]
Kusunose, Masaaki [3 ]
Shibayama, Ayumi [4 ]
Nakayasu, Kazuhito [5 ]
机构
[1] Natl Ctr Geriatr & Gerontol, 7-430 Morioka Cho, Obu 4748511, Japan
[2] Clin Nishimura, 4-3 Kohigashi, Kuri Cho, Ayabe 6230222, Japan
[3] Natl Ctr Geriatr & Gerontol, Dept Resp Med, 7-430 Morioka Cho, Obu 4748511, Japan
[4] Natl Ctr Geriatr & Gerontol, Dept Nursing, 7-430 Morioka Cho, Obu 4748511, Japan
[5] Kondo PP Inc, Data Res Sect, 17-25 Shimizudani Cho, Tennoujiku, Osaka 5430011, Japan
关键词
chronic obstructive pulmonary disease (COPD); disease severity; Global Initiative for Chronic Obstructive Lung Disease (GOLD); STaging of Airflow obstruction by Ratio (STAR); St. George's Respiratory Questionnaire (SGRQ); COPD Assessment Test (CAT); AIR-FLOW LIMITATION; COPD; MORTALITY; EXACERBATIONS; PREDICTORS; DYSPNEA; INDEX; RATIO; FEV1; FVC;
D O I
10.3390/diagnostics14060646
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In chronic obstructive pulmonary disease (COPD), there are two known classifications for assessing what is called disease severity. One is the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification, which is based on the post-bronchodilator value of FEV1 (% reference). The other is the STaging of Airflow obstruction by Ratio (STAR), with four grades of severity in subjects with an FEV1/FVC ratio <0.70: STAR 1 >= 0.60 to <0.70, STAR 2 >= 0.50 to <0.60, STAR 3 >= 0.40 to <0.50, and STAR 4 <0.40. Purpose: The aim of this study was to compare the staging of COPD using the GOLD and STAR classifications in clinical practice. Methods: We reanalyzed data from our outpatient cohort study, which included 141 participants with COPD from 2015 to 2023. We compared mortality and COPD-specific health status between the GOLD 1 to 4 groups and the STAR 1 to 4 groups. Results: By simple calculation, GOLD and STAR severity classes coincided in 75 participants (53.2%). The weighted Bangdiwala B value with linear weights was 0.775. The participants were observed for up to 95 months, with a median of 54 months. Death was confirmed in 29 participants (20.5%). In univariate Cox proportional hazards analyses, there was a significant difference in mortality between the GOLD 1 and GOLD 3 + 4 groups, with the GOLD 1 group used as the reference [hazard ratio 4.222 (95% CI 1.298-13.733), p = 0.017]. However, there was no statistically significant predictive relationship between STAR 1 and STAR 2, or between STAR 1 and STAR 3 + 4. St. George's Respiratory Questionnaire (SGRQ) Total and COPD Assessment Test (CAT) scores were significantly different between all GOLD groups, except for the CAT score between GOLD 1 and GOLD 2. The SGRQ Total and CAT scores were significantly different between STAR 1 and STAR 3 + 4, but not between STAR 1 and STAR 2. Conclusion: From the perspective of all-cause mortality and COPD-specific health status, the GOLD classification is more discriminative than STAR.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Clinical practice guidelines or personalized medicine in chronic obstructive pulmonary disease?
    Jose Soler-Cataluna, Juan
    ARCHIVOS DE BRONCONEUMOLOGIA, 2018, 54 (05): : 247 - +
  • [22] Chronic obstructive pulmonary disease phenotypes: Are they really useful in clinical practice?
    Akpinar, Evrim Eylem
    Hosgun, Derya
    EURASIAN JOURNAL OF PULMONOLOGY, 2019, 21 (03) : 143 - 147
  • [23] How will telemedicine change clinical practice in chronic obstructive pulmonary disease?
    Vitacca, Michele
    Montini, Alessandra
    Comini, Laura
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2018, 12
  • [24] Variability in clinical practice for chronic obstructive pulmonary disease in outpatient clinics
    Abad Arranz, Maria
    Calero Acuna, Carmen
    Romero Valero, Fernando
    Hidalgo Molina, Antonio
    Ayerbe Garcia, Ruth
    Aguilar Perez-Grovas, Ricardo Ismael
    Garcia Gil, Francisco
    Caballero Ballesteros, Laura
    Casas Maldonado, Francisco
    Sanchez Palop, Maria
    Segado Soriano, Alejandro
    Perez Tejero, Dolores
    Calvo Bonachera, Jose
    Hernandez Sierra, Barbara
    Domenech del Rio, Adolfo
    Arroyo Valera, Macarena
    Gonzalez Vargas, Francisco
    Cruz Rueda, Juan Jose
    Lopez-Campos Bodineau, Jose Luis
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [25] Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease
    Roche, N
    Lepage, T
    Bourcereau, J
    Terrioux, P
    EUROPEAN RESPIRATORY JOURNAL, 2001, 18 (06) : 903 - 908
  • [26] Ministry of Health Clinical Practice Guidelines: Chronic Obstructive Pulmonary Disease
    Lim, Tow Keang
    Chee, Cynthia
    Chow, Patsy
    Chua, Gerald
    Eng, Soo Kiang
    Goh, Soon Keng
    Kng, Kwee Keng
    Lim, Wai Hing
    Ng, Tze Pin
    Ong, Thun How
    Seah, Angeline
    Tan, Hsien Yung David
    Tee, Augustine
    Palanichamy, Vimal
    Yeung, Meredith
    SINGAPORE MEDICAL JOURNAL, 2018, 59 (02) : 76 - 86
  • [27] Implementation of the chronic obstructive pulmonary disease Assessment Test in clinical practice
    Abrams, Meghan E.
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2021, 33 (11) : 1066 - 1073
  • [28] Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease
    Miravitlles, M
    EUROPEAN RESPIRATORY JOURNAL, 2002, 20 (01) : 243 - 244
  • [29] Epidemiology, severity, and treatment of chronic obstructive pulmonary disease in the United Kingdom by GOLD 2013
    Raluy-Callado, Mireia
    Lambrelli, Dimitra
    MacLachlan, Sharon
    Khalid, Javaria Mona
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2015, 10 : 925 - 936
  • [30] Comparison of Australian and international guidelines for grading severity of chronic obstructive pulmonary disease
    Kyoong, A.
    Mol, S.
    Guy, P.
    Finlay, P.
    Strauss, B. J.
    Holmes, P.
    Bardin, P. G.
    INTERNAL MEDICINE JOURNAL, 2006, 36 (08) : 506 - 512